



Cite this: *RSC Adv.*, 2018, 8, 24084

The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: an *in vitro* and *in vivo* evaluation

Qi Zhang,^a Jing Wang,^a Hao Zhang,^a Dan Liu,^a Linlin Ming,^b Lei Liu,^a Yan Dong,^c Baiyu Jian^c and Defu Cai^{ib}*^a

In our recent study, hydrophobic cell-penetrating peptides (CPPs) were demonstrated as an effective method of improving cancer treatment. To provide more evidence and broaden the application range for this promising strategy of improving cancer treatment, novel hydrophobic CPP-modified (PFV-modified) nanoliposomes loaded with paclitaxel, termed PFV-Lip-PTX, were developed as a treatment for breast cancer. Physicochemical evaluations of PFV-Lip-PTX revealed spheroid-like regular vesicles of about 120 nm in diameter with negative charge. An *in vitro* release study indicated that PTX was released from the liposomes in a controlled and sustained manner. A cellular uptake study indicated that PFV-Lip-PTX exhibited higher internalization efficiency in MCF-7 cells than non-modified liposomes. It was also demonstrated that PFV modification improved the cytotoxicity of PTX *via* a hydrophobic interaction between the PFV-Lip and cell lipid membranes compared with non-modified liposomes. Moreover, *in vivo* studies demonstrated that the PFV-modified liposomes led to highly efficient targeting and accumulation in an MCF-7 xenograft tumor and improved the antitumor efficacy of PTX. Finally, PFV-Lip-PTX showed low systemic toxicity evidenced by fewer changes in the body weights of mice and no visible histological changes in major healthy organs. Therefore, our results indicate that PFV-Lip-PTX has great potential in tumor-targeting and effective antitumor treatment.

Received 26th April 2018
 Accepted 18th June 2018

DOI: 10.1039/c8ra03607a

rsc.li/rsc-advances

1. Introduction

Breast cancer is the most common cancer in women, and one of the three most common cancers worldwide, along with lung and colon cancers.¹ It is characterized by wild cell growth in breast tissues leading to metastasis, invasion of adjacent tissue and infiltration beyond the breasts. One in eight to ten women will develop breast cancer in their lifetime. In 2012, almost 1.7 million people were diagnosed worldwide and about half a million people died from this disease.² Although surgery is a preferred method to remove breast cancer, it is difficult to completely remove the tumor and inhibit its rapid recurrence. Thus, chemotherapy is required to supplement the treatment deficit of surgery. Among the most commonly used chemotherapeutic drugs, taxanes have been established as a viable treatment choice for breast cancer.³

Paclitaxel (PTX), a natural alkaloid from the Pacific yew, has a considerably wide therapeutic range against ovarian cancer,

breast cancer, non-small cell lung cancer, stomach cancer, head and neck carcinomas, advanced forms of Kaposi's sarcoma and acute leukemia.^{4,5} PTX exerts its action through binding to the β -subunit of tubulin, a component of microtubules that results in the formation of stable microtubule assemblies.⁶ Subsequent PTX blocks the mitotic checkpoint and arrests cells in the late G2 and M phases of the cell cycle.⁷ However, the significant activity of PTX in clinical applications is greatly restricted by its poor water solubility, low therapeutic index and severe side effects at high doses.⁸ Due to the low water solubility of PTX in conventional formulations, a mixture of Cremophor EL and dehydrated ethanol (50 : 50, v/v) was applied as a co-solvent in the first clinical formulation of PTX under the trade name of Taxol®.⁹ It is characterized by very low drug loading (1 wt%). Therefore, substantial amounts of Cremophor EL and ethanol are necessary to ensure an effective dose of PTX. However, many serious side effects including neutropenia, hypersensitivity, anaphylactic reactions, nephrotoxicity and neurotoxicity have been attributed to Cremophor EL, which remarkably impede dosing and often require clinical intervention.^{10,11} These negative side effects mean that the medical benefits obtained from PTX seem to have reached a plateau. Hence, the development of an improved delivery system for PTX is extremely desirable.

^aInstitute of Medicine and Drug Research, Qiqihar Medical University, Qiqihar 161006, P. R. China. E-mail: cai@qmu.edu.cn; Tel: +86-452-2663376

^bThe Third Affiliated Hospital, Qiqihar Medical University, Qiqihar 161006, P. R. China

^cCollege of Pharmacy, Qiqihar Medical University, Qiqihar, 161006, P. R. China



Fortunately, the introduction of nanotechnology in oncology could alleviate potential systemic toxicity and improve the therapeutic effect of PTX. A few successful nano-delivery formulations have already been accepted as alternative formulations of PTX on the market, such as Abraxane® (albumin-bound PTX nanoparticles), Lipusu® (PTX liposome injection) and Genexol-PM® (PTX poly(lactide-co-glycolic acid) micelles).¹² Well-designed nanocarriers for the delivery of PTX to tumor tissues might possess numerous appealing properties, such as increased PTX solubility, the ability to promote accumulation in tumor sites *via* passive and/or active targeting, reduced side effects and controlled release.¹³ Among the various existing delivery systems, liposomes are the most promising for clinical applications, as they exhibit high delivery efficiency, good biocompatibility, non-immunogenicity and the ability to encapsulate hydrophobic and hydrophilic drugs.¹⁴ However, compared to Taxol, PTX liposomes do not show a significant difference in response rate, and can also lead to the development of hematological and nervous system toxicity in patients.¹⁵ Its clinical effect in increasing survival is still unclear. Usually, it is difficult to achieve good outcomes when using liposomes as a clinical treatment, as they often cannot efficiently enter tumor cells.¹⁶ To overcome this difficulty, some specific functional moieties have been attached on the surfaces of liposomes for further functionalization on the basis of passive targeting.¹⁷ Among the many proposed strategies for improved delivery of liposomes, cell penetrating peptides (CPPs) have appeared as an achievable strategy and have led to encouraging results. One of the most remarkable properties of CPPs is their capability to deliver bioactive cargo with molecular weights several times greater than their own through the cell membrane.¹⁸ Since the discovery of the first CPPs in 1988, a variety of CPPs derived from natural, chimeric and synthetic sources have been used to transport small RNA/DNA, plasmids, antibodies and nanoparticles into specific sites of different cells.¹⁹ However, most CPPs are positively charged and are classified as cationic CPPs, which present toxicity alongside cellular uptake improvement.

Hydrophobic CPPs have a low net charge, contain only non-polar residues and have a hydrophobic motif that is crucial for uptake. They exhibit low toxicity to normal cells, which

contrasts what is observed for most cationic CPPs.^{20,21} Moreover, some hydrophobic CPPs can directly translocate across lipid cell membranes, which could be especially advantageous as they would immediately get to the cytosol, eliminating the risk of endosomal entrapment.²² Several hydrophobic CPPs have been confirmed to be efficient in delivering therapeutic molecules into cells, such as the signal sequence from integrin $\beta 3$ (VTVLALGALAGVGVG),²³ FGF (PIEVCMYREP)²⁴ and a short sequence QLPVM.²⁰ In our previous study, the typical hydrophobic CPP, PFVYLI (PFV), which is derived from $\alpha 1$ -antitrypsin, was introduced to modify doxorubicin-loaded liposomes for the first time. The modified liposomes were capable of facilitating intracellular delivery as well as improving antitumor efficiency without apparent toxicity.²⁵ Furthermore, PFV serving as a carrier could efficiently facilitate the intracellular transport of cargoes such as siRNA, fluorescent probes and proapoptotic peptides into a number of different cell lines.^{26–28} However, further proof is needed to support the conclusion that the introduction of hydrophobic CPPs is an appropriate choice to improve the intracellular delivery of nanocarriers.

To verify that functionalizing liposomes with PFV would facilitate their intracellular delivery *via* the hydrophobic interaction between PFV and cell lipid membranes, we synthesized a novel PFV-conjugated PEG-DSPE polymer and incorporated it into the liposomes. The prepared PFV-Lip was characterized in terms of particle size, zeta potential, morphology, encapsulation efficiency and drug release. The *in vitro* cellular uptake of the PFV-modified liposomes was investigated *via* flow cytometry, confocal microscopy and HPLC analysis on MCF-7 cells, and the *in vitro* cytotoxicity was determined through an SRB assay. Finally, the *in vivo* distribution and anti-tumor efficacy of PFV-Lip-PTX were investigated in MCF-7 tumor-bearing mice. The systemic toxicity of PFV-Lip-PTX after administration was also evaluated (Fig. 1).

2. Experimental

2.1 Materials

Paclitaxel (PTX) was provided by Dalian Meilun Biotech Co., Ltd. (Dalian, China). Egg yolk phosphatidylcholine (EPC, LIPOID E-




Fig. 1 Scheme of PFVYLI-modified liposomes for targeted delivery of PTX *in vivo*.



80) was obtained from LIPOID GmbH (Ludwigshafen, Germany). Cholesterol (Chol), sephadex G-50, Cou6, Hoechst 33258, sulforhodamine B (SRB), trichloroacetic acid (TCA) and Tris base were all purchased from Sigma-Aldrich (Shanghai, China). Near-infrared lipophilic carbocyanine dye DiR was obtained from Biotium, Inc. (Hayward, USA). PEG₂₀₀₀-DSPE and *N*-hydroxysuccinimidyl-PEG₂₀₀₀-DSPE were purchased from ToYong Biotech Co., Ltd. (Shanghai, China). PFVYLI was provided by China Peptides Co., Ltd. (Shanghai, China). All other chemicals and reagents were purchased from Sigma-Aldrich (Shanghai, China) unless otherwise stated.

Female BALB/c nude mice of 18–20 g were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Before the experiment, they were kept under SPF conditions for 1 week and were allowed free access to standard food and water. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Qiqihar Medical University and experiments were approved by the Animal Ethics Committee of Qiqihar Medical University.

2.2 Cell culture

The human breast cancer cell line MCF-7 was obtained from the Institute of Basic Medical Science, Chinese Academy of Medical Science (Beijing, China). The MCF-7 cells were cultured in RPMI-1640 medium (Macgene, China) supplemented with 10% FBS (Gibco, USA) and 1% penicillin–streptomycin solution (Macgene, China) at 37 °C in 5% CO₂ air.

2.3 Conjugation of PFV peptide with NHS-PEG-DSPE

PFV-PEG-DSPE was synthesized in our laboratory according to a previously reported method.²⁵ PFV was conjugated with NHS-PEG-DSPE through a nucleophilic substitution reaction. Briefly, PFV peptide and NHS-PEG₂₀₀₀-DSPE in a 1 : 2 molar ratio were dissolved in anhydrous DMF, and the pH of the reaction mixture was adjusted to 8.0–9.0 with triethylamine. The reaction was kept at room temperature under moderate stirring and the reaction was monitored by HPLC (Waters, USA). After 144 h, the reaction product was subjected to dialysis (MWCO 3500 Da) against deionized water to remove the unconjugated PFV peptide. Finally, the dialysate was lyophilized and stored at –20 °C until required. The product was identified using a MALDI-TOF mass spectrometry (Bruker Daltonics, USA).

2.4 Preparation and characterization of various drug-loaded liposomes

The thin-film hydration method was used to prepare the liposomes loaded with PTX or fluorescent dye (Cou6 or DiR) as described previously.²⁹ Typically, 15.9 mg of EPC, 4.1 mg of Chol, 4.7 mg of PEG₂₀₀₀-DSPE and 1.5 mg of PFV-PEG₂₀₀₀-DSPE were used in the preparation of the PFV-modified liposomes. For the unmodified liposomes, 15.9 mg of EPC, 4.1 mg of Chol, and 6.0 mg of PEG₂₀₀₀-DSPE were used. 1.0 mg of PTX or 10 μg of fluorescent dye were added into the liposomal compositions to prepare drug-loaded or fluorescence-labeled liposomes, respectively. Lipid mixtures with PTX or fluorescent dye were co-dissolved in 35 mL dichloromethane, and the organic solvent

was removed by rotary evaporation. Then the obtained film was further dried and stored under vacuum overnight. The lipid film was hydrated with phosphate buffer (pH 7.4), followed by sonication at 37 °C for 1 h until a clear solution was obtained. The liposome suspension was extruded through polycarbonate membranes with a pore size of 220 nm followed by gel filtration over a Sephadex G-50 column to remove the unencapsulated PTX or fluorescent dye. The liposomes were stored at 4 °C and used within 2 weeks of preparation.

The particle sizes and zeta-potentials of different liposomes were determined by dynamic light scattering (DLS) using a Nicomp 380ZLS (PSS, USA). The analysis was performed with 633 nm laser light at a scattering angle of 90° at 25 °C. The liposome solution was diluted 100-fold with PBS before measurement. Three measurements were taken for each sample. Transmission electron microscopy (Hitachi HT-7700, Japan) was used to observe the morphology of the liposomes. The liposome solution was diluted 10-fold with water and a drop of the diluted solution was placed on a carbon film and negatively stained with 1% phosphotungstic acid. After drying in air, sample analyses were carried out on a TEM with an acceleration of 100 kV.

The encapsulation efficiency (EE) of PTX in liposomes was quantified using a HPLC system. Liposome solution was diluted 10-fold with methanol, and was then eluted on an Agilent TC-C18 column (250 × 4.6 mm id, 5 μm particles) at a temperature of 30 °C. The mobile phase consisted of acetonitrile and water (60 : 40, v/v), which was delivered at a flow rate of 1.0 mL min⁻¹. The injection volume was 10 μL and the PTX absorbance was measured at a wavelength of 227 nm. The EE was calculated by the following equation: EE = $W/W_0 \times 100\%$, where W_0 and W represent the amounts of PTX in the liposomes before and after passing over the Sephadex G-50 column, respectively.

The release profile of PTX from PFV-Lip-PTX was investigated using a dialysis method. Briefly, a volume of 1.0 mL of purified liposome suspension was mixed with 3 mL of RPMI-1640 medium containing 10% FBS, and transferred into a dialysis bag (MWCO 12000–14000 Da) sealed at both ends. Then the bag was immersed in 30 mL of release medium (1.0 M sodium salicylate) at 37 °C, followed by gentle shaking at 100 rpm. At predetermined time intervals (2, 4, 6, 8, 12 and 24 h), a 1.0 mL aliquot of the release medium was collected and replaced with an equal volume of fresh medium. After the 24 h period of the release test, the released amount of PTX in each time point was measured *via* HPLC.

2.5 *In vitro* cellular uptake studies

2.5.1 Flow cytometry analysis. For cellular uptake analysis using flow cytometry, MCF-7 cells were seeded into 12-well plates at a density of 1×10^5 cells per well and were allowed to attach overnight until 70–80% confluence was reached. Then the medium was removed and the cells were washed twice with PBS, and incubated with free Cou6, Lip-Cou6 and PFV-Lip-Cou6, diluted with serum-free medium at the final concentration of 100 ng mL⁻¹ for 1 h at 37 °C. Then, the cells were detached by trypsinization, pelleted by centrifugation and



rinsed three times with cold PBS (pH = 7.4). Finally, the mean Cou6 fluorescence intensity inside the cells was measured using a FACScan flow cytometer (Becton Dickinson FACSCalibur, USA), with 10 000 events collected, excitation at 488 nm and detection at 560 nm. Each assay was performed in triplicate.

2.5.2 Laser confocal microscopy analysis. For the confocal microscopy study, MCF-7 cells were cultured on microscope slides in a 24-well plate (5×10^4 cells per well) for 24 h until total adhesion was achieved. Then the cells were treated with free Cou6, Lip-Cou6 and PFV-Lip-Cou6 at a Cou6 concentration of 100 ng mL^{-1} . After 1 h incubation, the culture medium was removed and the cells on the microscope slides were washed three times with ice-cold PBS. Then the cells were fixed with 4% paraformaldehyde solution for 20 min, followed by cell nuclei staining with Hoechst 33258 ($10 \text{ } \mu\text{g mL}^{-1}$) for another 20 min and washing with PBS three times. Finally, fluorescent images of the cells were captured and analyzed using a LSM710 laser confocal microscope (Zeiss, Germany).

2.5.3 HPLC analysis. For the HPLC study, MCF-7 cells were seeded at a density of 3×10^5 cells per well in 6-well plate and incubated at $37 \text{ }^\circ\text{C}$ for 24 h to allow cell attachment. Then the medium was removed and the cells were washed twice with PBS, and incubated with free PTX, Lip-PTX and PFV-Lip-PTX diluted with serum-free medium to a PTX final concentration of $10 \text{ } \mu\text{g mL}^{-1}$ for 3 h at $37 \text{ }^\circ\text{C}$. Then, the cells were detached by trypsinization, pelleted by centrifugation and rinsed three times with cold PBS (pH = 7.4). Cells were then treated with Radio-Immunoprecipitation Assay (RIPA) lysis buffer for 30 min, and methanol was added to extract PTX. The extraction solution was centrifuged at 12 000 rpm for 10 min and the supernatant was analyzed using HPLC to measure PTX uptake by MCF-7 cells. HPLC detection conditions for PTX were similar to those described in Section 2.4.

2.6 *In vitro* cytotoxicity studies

The cytotoxic effects of free PTX, Lip-PTX and PFV-Lip-PTX against MCF-7 cells were determined using the sulforhodamine B (SRB) colorimetric assay. Briefly, MCF-7 cells were cultured in 96-well plates at a density of 5000 cells per well. After incubation for 24 h, cells were treated with a series of concentrations of free PTX, Lip-PTX and PFV-Lip-PTX ($0.25\text{--}256 \text{ ng mL}^{-1}$) diluted with complete RPMI-1640 medium for 48 h at $37 \text{ }^\circ\text{C}$. Then the cells were fixed with 10% cold trichloroacetic acid, followed by washing and drying in the air. Subsequently, the fixed cells were stained with 0.4% SRB for 30 min, washed with 1% acetic acid and dissolved in 10 mM Tris base solution. Finally, the absorption representing cell viability was measured using a plate reader (Thermo Scientific, Multiskan FC, USA) at 540 nm. All data were calculated as the percentages of viable cells relative to the survival of the control group (cells treated with medium) and presented as the mean \pm SD ($n = 3$). The IC_{50} values were calculated using SPSS software.

2.7 *In vivo* distribution study of PFV-Lip-DiR by live imaging

The MCF-7 tumor xenograft model was established on BALB/c nude mice by subcutaneous inoculation of MCF-7 cells ($2 \times$

10^6) in the right armpit. When the tumor volume reached $50\text{--}100 \text{ mm}^3$, the MCF-7 tumor-bearing mice were randomly divided into three groups and received intravenous injections of 0.2 mL free DiR, Lip-DiR and PFV-Lip-DiR *via* the tail vein. The final concentration of DiR was $5 \text{ } \mu\text{g mL}^{-1}$. At 2, 4, 8, 12, 24, 36 and 48 h after administration, mice were anesthetized with 2% isoflurane and the distributions of different formulations were visualized using an *In Vivo* Imaging System (Carestream Health, USA). After that, the mice were sacrificed immediately by cervical dislocation. The tumors and organs were collected and *ex vivo* fluorescence images were obtained on the same system.

2.8 *In vivo* antitumor efficacy and toxicity studies

In vivo antitumor efficacy was assessed using the xenograft tumor model as established above. When the tumor volume reached approximately 100 mm^3 , the mice were randomly assigned into 4 groups and treated with 0.2 mL of physiological saline, Taxol, Lip-PTX or PFV-Lip-PTX *via* the tail vein at a dosage of 10 mg PTX/kg body weight on every second day for a total of 5 doses. The mice were then monitored every other day for tumor volumes and body weights. Tumor volume was calculated as $V = (\text{length} \times \text{width}^2)/2$. At the end point of the experiment, the mice were sacrificed, and the tumors were excised and weighed to evaluate the *in vivo* anti-tumor efficacy. The major organs were excised to make H&E staining sections, which were observed using an optical microscope for histological analyses to evaluate the toxicity of the PTX solution and liposomes.

2.9 Statistical analysis

All the quantitative data were presented as the mean \pm SD, and Student's *t* test or one-way analysis of variance was performed to evaluate significance among groups. A value of *P* less than 0.05 or 0.01 was considered to be statistically significant or highly significant.

3. Results and discussion

3.1 Conjugation of PFV peptide with NHS-PEG-DSPE

The targeting copolymer of PFV-PEG-DSPE was synthesized by conjugating isoleucine residue of PFV to NHS-PEG₂₀₀₀-DSPE. According to the HPLC chromatograms in Fig. 2B, the retention time of unreacted PFV was about 21.2 min and the conjugation efficiency was about 79.2% after 6 days. These results indicate that PFV had been conjugated to PEG-DSPE. The formation of PFV-PEG₂₀₀₀-DSPE was further confirmed using MALDI-TOF mass spectrometry. As shown in the MALDI-TOF MS spectra (Fig. 2C), the molecular weight (MW) of the reaction product was approximately 3655 Da, which was in good agreement with the theoretical MW, confirming that the targeting copolymer of PFV-PEG-DSPE had been successfully prepared.

3.2 Preparation and characterization of various drug-loaded liposomes

Fig. 2A shows a schematic representation of the PFV-modified liposomes. The physicochemical properties of PTX, coumarin-6 (Cou6) and 1,10-dioctadecyltetramethyl indotricarbo-cyanine






Fig. 2 Characteristics of PFV-modified liposomes loaded with PTX. (A) Schematic representation of PFV-modified Liposomes (PFV-Lip). (B) HPLC spectra monitoring the reaction of PFV with NHS-PEG₂₀₀₀-DSPE. (C) MALDI-TOF MS spectra of PFV-PEG₂₀₀₀-DSPE. (D) Size distribution graph of PFV-Lip-PTX obtained via dynamic light scattering. (E) Transmission electron microscopy (TEM) image of PFV-Lip-PTX. (F) *In vitro* release of PTX from Lip-PTX and PFV-Lip-PTX ($n = 3$).

iodide (DiR) loaded liposomes with or without PFV modification are summarized in Table 1. Cou6 and DiR were used as hydrophobic fluorescent probes to investigate cellular uptake and the *in vivo* distribution of PFV-Lip. It has been previously reported that liposome size, especially aggregation size in the presence of serum, is one of the most important factors governing the fate of liposomes *in vivo*.³⁰ In this study, the mean particle sizes of various liposomes were in the range of 105.4–123.0 nm, with low polydispersity index (PDI) values of less than 0.25. This size range is acknowledged as the best particle size for EPR. A typical particle size distribution graph of PFV-Lip-PTX is shown in Fig. 2D. The morphological structure was investigated using TEM (Fig. 2E). The TEM image shows that PFV-Lip-PTX comprises spheroid-like regular vesicles that are smaller than 200 nm in diameter, which is identical to the value obtained using DLS. Additionally, all liposomes are slightly charged with negative zeta potentials of less than -3 mV, meaning that they are in the ideal charge range to accumulate in tumors efficiently and avoid nonspecific organ uptake.³¹ On the other hand, the EEs are all higher than 90%. These results indicate that PFV modification would not bring about any significant changes to the physicochemical properties of the liposomes, and thus may not have any influence during the comparison of these two liposomal formulations.³²

In vitro release studies are an essential step during drug development, because they not only allow for quality control of formulations, but also reveal the *in vivo* performance of the product.³³ The release profiles of PTX from different liposomes are presented in Fig. 2F. No burst release was detected, and similar release kinetics was observed between Lip-PTX and PFV-Lip-PTX. The release rates of PTX in two liposomes were less than 10% at the initial 1 h and approximately 50% at 24 h, indicating that the PTX remained encapsulated within the liposomes, thus leading to a delayed drug release. This is beneficial for tumor therapy, as it may prevent rapid leakage during systemic circulation and ensure that the PTX-loaded liposomes can reach and accumulate in the tumor sites.

Generally, the above results reveal that the PFV modification does not bring about visible changes to liposomes in terms of their size, surface potential, stability and release kinetics. This was favorable for the following comparison of these two liposomal systems in cell and animal studies.

3.3 *In vitro* cellular uptake studies

3.3.1 Flow cytometry analysis. To evaluate the ability of the PFV-modified liposomes to improve intracellular delivery, cellular uptake analysis was performed on MCF-7 cells by quantitative flow cytometry. Fig. 3A indicates that the cellular

Table 1 Characteristics of various drug-loaded liposomes ($n = 3$, mean \pm SD)

	Size (nm)	PDI	Zeta potential	Encapsulation efficiency (%)
Lip-PTX	119.0 \pm 5.3	0.210 \pm 0.035	-2.69 ± 0.89	92.2 \pm 4.3
PFV-Lip-PTX	123.0 \pm 7.1	0.194 \pm 0.025	-1.53 ± 0.63	90.7 \pm 2.6
Lip-Cou6	110.8 \pm 5.7	0.183 \pm 0.037	-2.41 ± 0.97	93.3 \pm 1.9
PFV-Lip-Cou6	106.8 \pm 4.5	0.141 \pm 0.029	-2.83 ± 0.35	95.6 \pm 3.1
Lip-DiR	105.4 \pm 4.8	0.196 \pm 0.031	-2.27 ± 0.48	94.1 \pm 2.5
PFV-Lip-DiR	109.4 \pm 3.2	0.218 \pm 0.046	-1.36 ± 0.21	92.1 \pm 3.2






Fig. 3 Cellular uptake study of free Cou6, Lip-Cou6 and PFV-Lip-Cou6 on MCF-7 cells at 37 °C for 1 h. The final concentration of Cou6 was 100 ng mL⁻¹. (A) Flow cytometric quantitative determination of Cou6 uptake. (B) Quantitative analysis of Cou6 uptake based on flow cytometric plots. Each bar represents the mean fluorescence intensity \pm SD ($n = 3$), * $p < 0.01$. (C) Laser scanning confocal microscopy images of cells incubated with Lip-Cou6 (A1-4), PFV-Lip-Cou6 (B1-4) and free Cou6 (C1-4). Green and blue indicate the fluorescence of Cou6 and Hoechst 33258, respectively. Scale bars represent 20 μ m.

uptake of the PFV-modified liposomes was much higher than that of the unmodified liposomes. In more detail, the intracellular Cou6 level for PFV-Lip-Cou6 was 2.3-fold higher than that of Lip-Cou6 (Fig. 3B). The difference in cellular uptake between Lip-Cou6 and PFV-Lip-Cou6 actually indicates the difference between non-PFV and PFV modification, namely that PFV modification can facilitate the uptake of liposomes. Furthermore, the highly hydrophobic free Cou6, as a positive control, demonstrated the highest cellular Cou6 level, as it can go straight into the cell lipid membranes without release from liposomes, and then diffuse into the cell, leading to a greater extent of cellular accumulation.³⁴

3.3.2 Laser confocal microscopy analysis. The intracellular accumulation and distribution of Cou6-loaded liposomes in MCF-7 cells was also analyzed using laser confocal microscopy. Fig. 3C shows the confocal microscopy images of MCF-7 cells after 1 h incubation with free Cou6, Lip-Cou6 and PFV-Lip-Cou6 at 37 °C. Free Cou6, which was taken as the positive control group, showed the highest green fluorescence intensity, due to the same reason mentioned above. For PFV-Lip-Cou6, the microscopy images displayed more green fluorescence in the cell cytoplasm than Lip-Cou6, which demonstrated that PFV modification could enhance binding and penetration of the

liposomes into the tumor cells. These results are in accordance with the above quantitative study of cellular uptake obtained from flow cytometry.

3.3.3 HPLC analysis. The cellular uptake of PTX in MCF-7 cells was also quantitatively evaluated using HPLC after different treatments with various PTX formulations. As is clearly shown in Fig. 4, the cellular uptake of the PTX formulations in the MCF-7 cells followed the order: free PTX > PFV-Lip-PTX > Lip-PTX. Compared to Lip-PTX, the PFV-Lip-PTX group showed 1.6 times higher intracellular PTX content, demonstrating a statistically significant difference. Free PTX as the positive control showed the highest intracellular PTX content due to the same reason mentioned above.

Ligand- or antibody-conjugated nanocarriers exhibit promising effects only in certain types of cancers that highly express the correlated specific receptors.³⁵ However, patterns of receptor expression are diverse among different types of tumors and sometimes even within the same tumor, which limits the application of ligand- or antibody-based drug delivery systems.³⁶ Theoretically, any interaction between cells and the specific molecules may be applied to enhance nanoparticle intracellular delivery. The hydrophobic interaction between hydrophobic peptides and cell membranes is another type of important interaction, which is often ignored or underestimated.²¹ The hydrophobic interaction is the primary driving force in a number of physiological events in the human body, including cell signaling, the formation of ion channels, cytolysis and cellular recognition.³⁷ In this study, all the flow cytometry, confocal microscopy and HPLC results demonstrate that PFV modification obviously enhances the cellular uptake of liposomes on MCF-7 cells. This is attributed to the hydrophobic feature of PFV, which facilitates the interaction between the PFV-Lip and cell lipid membranes, thus improving the liposome intracellular uptake.

3.4 In vitro cytotoxicity studies

The first step in the therapeutic efficacy evaluation of the PFV-Lip-PTX formulation for breast cancer was to perform




Fig. 4 Cellular uptake study of free PTX, Lip-PTX and PFV-Lip-PTX on MCF-7 cells at 37 °C for 3 h. The final concentration of PTX was 10 μ g mL⁻¹. Each bar represents mean \pm SD ($n = 3$), * $p < 0.01$.






Fig. 5 *In vitro* cytotoxicity of free PTX, Lip-PTX, and PFV-Lip-PTX on MCF-7 cells by SRB assay after treatment with indicated concentrations of PTX formulations for 48 h. Each bar represents mean \pm SD ($n = 3$). * and ** indicate statistically different $p < 0.05$ and $p < 0.01$.

a cytotoxicity assay on MCF-7 cells using an SRB method. Fig. 5 shows the cell viabilities of free PTX, Lip-PTX and PFV-Lip-PTX under a series of PTX concentrations against MCF-7 cells. The results demonstrate that free PTX, Lip-PTX and PFV-Lip-PTX could inhibit cell proliferation in a concentration-dependent manner. The IC_{50} values of free PTX, Lip-PTX and PFV-Lip-PTX were calculated to be 3.44 ± 0.87 , 34.98 ± 6.14 and 11.23 ± 3.69 $ng\ mL^{-1}$, respectively, indicating that the cytotoxicity of PFV-Lip-PTX was significantly higher than that of Lip-PTX. It is obvious that free PTX exhibited stronger cytotoxicity than the two liposomal PTX formulations. As expected, PFV modification significantly enhanced the cytotoxicity of liposomal PTX at a concentration range of 4–256 $ng\ mL^{-1}$.

PTX could inhibit cell microtubule disassembly and promote the formation of unusually stable microtubules, thereby disrupting the normal dynamic reorganization of the microtubule network required for mitosis and cell proliferation, and finally causing cell apoptosis.³⁸ Thus, in this study, we observed that PTX could inhibit MCF-7 cell proliferation in a concentration-

dependent manner. The cytotoxicity of PTX formulations against the MCF-7 cells followed the order: free PTX > PFV-Lip-PTX > Lip-PTX. Free PTX exhibited better cytotoxicity with a lower IC_{50} value than Lip-PTX and PFV-Lip-PTX, owing to the different internalization mechanisms of free PTX and PTX-loaded liposomes, and the sustained release manner of PTX from the liposomes. Free PTX could directly enter cells *via* passive diffusion and be effective, whereas the drug-loaded liposomes were mainly taken up by cells *via* the endocytic pathway and then the drug must be released to exert anticancer activity.³⁹ The IC_{50} of the PFV-Lip-PTX group was found to be 3.1 times higher than that of Lip-PTX. The hydrophobic interaction of PFV with cell membranes could facilitate the cellular uptake of the liposomes, and then release PTX for anticancer effect. These results further confirm that the cellular uptake of the liposomes could be enhanced by the attachment of PFV on the surface of the liposomes, hence promoting the effectiveness of the PTX treatment.

3.5 *In vivo* distribution study of PFV-Lip-DiR by live imaging

To evaluate the *in vivo* biodistribution and tumor-targeting ability of the PFV-modified liposomes, free DiR, Lip-DiR and PFV-Lip-DiR were injected intravenously into mice bearing MCF-7 tumor xenografts and were monitored using a fluorescence imaging system. In the free DiR group, the fluorescence intensity in the tumor was negligible over a period of 48 h, revealing no specific accumulation of free DiR in the tumor (data not shown). As shown in Fig. 6A, the fluorescence signals in the tumors were detected in both the Lip-DiR and PFV-Lip-DiR groups at 2 h after administration. Both groups displayed specific fluorescence distribution in tumors over time through passive targeting. However, the PFV-Lip-DiR group had high tumor targeting capability and resulted in stronger fluorescence intensity in the tumor than the Lip-DiR control group, especially from 12 h to 48 h after administration. More importantly, the tumor accumulation of DiR in the PFV-Lip-DiR group occurred much earlier and lasted longer at a higher level than that in Lip-




Fig. 6 (A) Representative whole-body *in vivo* fluorescence images of MCF-7 tumor-bearing BALB/c nude mice were injected intravenously with different DiR-loaded liposomes at different time points. (B) *Ex vivo* fluorescent images of dissected tumors and major organs of mice sacrificed after 48 h circulation in the body.



DiR group. The fluorescence intensity began to decrease from 24 h post-injection in the Lip-DiR group, whereas in the PFV-Lip-DiR group, the fluorescence intensity in the tumors gradually increased and was still obvious until 48 h. The *ex vivo* fluorescence images of the tumors and major organs at 48 h following *i.v.* injection revealed much stronger tumor fluorescence intensity in the PFV-Lip-DiR group than in the Lip-DiR group (Fig. 6B). As the typical tissue in RES, the livers and spleens had high fluorescence signals in both the Lip-DiR and Lip-SSLs-DiR groups, as expected. In brief, it was evident that the liposomes could target MCF-7 tumor tissue on the basis of the EPR effect after they were injected *via* the tail vein, and the PFV modification could further enhance the favorable distribution of PFV-Lip-DiR in the tumor site.

DiR, a near-infrared fluorescence probe, was utilized to label the liposomes as it could effectively reduce the interference caused by the animal auto-fluorescence.⁴⁰ Compared with unmodified Lip-DiR, PFV-Lip-DiR showed a stronger fluorescence distribution in the tumor from 12 h to 48 h after administration, which was still significant at 48 h. It has been widely recognized that timely internalization by tumor cells can reduce the liposomes from re-entering systemic circulation.²⁰ The higher tumor distribution of PFV-Lip is probably due to PFV modification increasing the internalization, before PFV-Lip could re-enter systemic circulation, allowing PTX to exert its therapeutic effects inside the cells.⁴¹

3.6 *In vivo* antitumor efficacy and toxicity studies

The PFV-modified liposomes showed definite antitumor effects *in vitro*. Therefore, the *in vivo* anti-tumor efficiency and systemic toxicity of PFV-Lip-PTX were further investigated. Fig. 7 displays the anti-tumor effects of various PTX formulations against MCF-7 tumor-bearing BALB/c nude mice. Based on the tumor volume curve in Fig. 7A, tumor growth in the physiological saline group was more rapid than that in all PTX treatment groups. When compared to free PTX and Lip-PTX groups, the PFV-Lip-PTX group showed outstanding tumor suppression activity during the total test process and was significantly different ($p < 0.05$). At

the end of the experiment, the *ex vivo* tumor weight of different treatment groups in Fig. 7B further confirmed that PFV-Lip-PTX exhibited significant tumor inhibition compared with Lip-PTX in the MCF-7 tumor-bearing mouse model. These results clearly indicate the greater tumor suppressive efficacy of our established PFV-Lip-PTX. The enhanced antitumor efficacy of PFV-Lip-PTX may be explained as follows: (1) negatively-charged PFV-Lip-PTX in circulation interacts less with plasma proteins, so it can resist non-specific protein absorption and escape RES rapid elimination;⁴² (2) the particle sizes of PFV-Lip-PTX are in the ideal range to take advantage of the EPR effect for tumor therapy, inducing greater accumulation of PFV-Lip-PTX into the tumor tissue *via* the EPR effect;⁴³ (3) the liposomes possess excellent stability; and (4) PFV modification increases the cellular uptake of PFV-Lip-PTX to enhance cytotoxicity in breast cancer cells.

Mouse body weight changes in all groups, as an indicator of systemic toxicity, were measured simultaneously. As shown in Fig. 8, the body weights of mice in the control group slightly increased, and all the PTX treatment groups did not show sharp body weight loss. The body weight of mice in the Taxol group decreased to a greater extent than those in the PFV-Lip-PTX-treated group, suggesting the low systemic toxicity of PFV-Lip-PTX. The histological examination of several healthy organs of mice following treatment was conducted using H&E staining (Fig. 9). H&E staining showed that PFV-Lip-PTX did not cause visible histological changes to the major healthy organs over the duration of the experiment. These results confirm that PFV-modified liposomes can provide better anti-tumor effects with low systemic toxicity.

In addition to the treatment for breast cancer indicated in this study, we believe that the PFV-modified liposomes could be used for the delivery of different therapeutic or imaging agents to heterogeneous tumors, based on our studies into the mechanism of cellular uptake. Although the interaction between PFV and the tumor cell membrane is nonspecific, combined with the EPR effect of nano-sized liposomes, PFV-Lip shows potential to enhance the tumor tissue distribution and improve the antitumor therapy. In this way, this study with PFV is similar to




Fig. 7 *In vivo* antitumor efficacy and toxicity studies in MCF-7 human breast tumor-bearing BALB/c nude mice. Mice were treated with saline, Taxol, Lip-PTX and PFV-Lip-PTX every other day 5 times at a dosage of 10 mg kg⁻¹ PTX. (A) Tumor volume changes of mice treated with different PTX-loaded formulations. (B) The weight of the excised tumor masses from different treatment groups. The black arrows note the day of administration. Data are presented as mean \pm SD ($n = 6$). Notes: * $p < 0.01$ vs. saline; ** $p < 0.05$ vs. taxol; # $p < 0.05$ vs. Lip-PTX.






Fig. 8 Body weight changes of mice during anti-tumor efficacy study ($n = 6$). Notes: * $p < 0.01$ vs. saline; ** $p < 0.05$ vs. PFV-Lip-PTX.




Fig. 9 Representative light microscopy images of several healthy organ ($\times 200$) tissue sections with H&E staining.

previous research on cyclosporine A and QLPVM-functionalized liposomes, and PFV-, CSA- and QLPVM-modified systems are generally similar to CPP- or target ligand-modified liposomes.^{20,21,44}

4. Conclusions

PFVYLL, a low toxicity hydrophobic CPP, was successfully used to modify liposomes (PFV-Lip) to deliver PTX for the first time. PFV-Lip-PTX showed remarkable characteristics including ideal size and charge, narrow size distribution, high encapsulation efficiency and a controlled, sustained release profile. We demonstrated that PFV modification could enhance the binding of PFV-Lip to cancer cells *via* a hydrophobic interaction, and

thus facilitate the intracellular delivery of liposomes into cancer cells. The results of cytotoxicity, *in vivo* distribution and anti-tumor efficacy experiments confirmed the superior therapeutic efficacy of PFV-Lip-PTX *in vitro* and *in vivo*. Furthermore, PFV-Lip-PTX displayed less systemic toxicity in terms of body weight changes and histological section observations. It is believed that PFV-Lip can provide us with a new perspective based on hydrophobicity, which is different to that exhibited by classic cationic CPPs. Consequently, PFV-Lip represents a promising platform for the improvement of therapeutic efficacy and reduction of drug toxicity, which may be widely applicable to the delivery of different types of chemotherapy drugs or imaging agents to various tumors.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The project was financially supported by the Natural Science Foundation of Heilongjiang Province of China (No. H2015069).

References

- 1 N. Harbeck and M. Gnant, *Lancet*, 2017, **389**, 1134–1150.
- 2 L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent and A. Jemal, *Ca-Cancer J. Clin.*, 2015, **65**, 87–108.
- 3 N. S. El Saghir, A. Tfayli, H. A. Hatoum, Z. Nacheff, P. Dinh and A. Awada, *Crit. Rev. Oncol. Hematol.*, 2011, **80**, 433–449.
- 4 F. Ravar, E. Saadat, M. Gholami, P. Dehghankelishadi, M. Mahdavi, S. Azami and F. A. Dorkoosh, *J. Controlled Release*, 2016, **229**, 10–22.
- 5 Y. Y. Shen, Z. K. Pi, F. Yan, C. K. Yeh, X. J. Zeng, X. F. Diao, Y. X. Hu, S. P. Chen, X. Chen and H. R. Zheng, *Int. J. Nanomed.*, 2017, **12**, 5613–5629.
- 6 K. L. Crossin and D. H. Carney, *Cell*, 1981, **27**, 341–350.
- 7 S. P. Akhlaghi, S. Saremi, S. N. Ostad, R. Dinarvand and F. Atyabi, *J. Nanomed. Nanotechnol.*, 2010, **6**, 689–697.
- 8 A. Safavy, *Curr. Drug Delivery*, 2008, **5**, 42–54.
- 9 P. Ma, S. R. Benhabbour, L. Peng and R. J. Mumper, *Cancer Lett.*, 2013, **334**, 253–262.
- 10 L. B. Ling, Y. W. Du, M. Ismail, R. Y. He, Y. P. Hou, Z. L. Fu, Y. Zhang, C. Yao and X. S. Li, *Int. J. Pharm.*, 2017, **526**, 11–22.
- 11 R. B. Weiss, R. C. Donehower, P. H. Wiernik, T. Ohnuma, R. J. Gralla, D. L. Trump, J. R. Baker Jr, D. A. Van Echo, D. D. Von Hoff and B. Leyland-Jones, *J. Clin. Oncol.*, 1990, **8**, 1263–1268.
- 12 Z. P. Zhang, L. Mei and S. S. Feng, *Expert Opin. Drug Delivery*, 2013, **10**, 325–340.
- 13 S. Singh and A. K. Dash, *Crit. Rev. Ther. Drug Carrier Syst.*, 2009, **26**, 333–372.
- 14 P. P. Deshpande, S. Biswas and V. P. Torchilin, *Nanomedicine*, 2013, **8**, 1509–1528.
- 15 X. Xu, L. Wang, H. Q. Xu, X. E. Huang, Y. D. Qian and J. Xiang, *Asian Pac. J. Cancer Prev.*, 2013, **14**, 2591–2594.
- 16 O. C. Farokhzad and R. Langer, *ACS Nano*, 2009, **3**, 16–20.



- 17 J. W. Sun, L. Jiang, Y. Lin, E. M. Gerhard, X. H. Jiang, L. Li, J. Yang and Z. W. Gu, *Int. J. Nanomed.*, 2017, **12**, 1517–1537.
- 18 C. P. Cerrato, K. Kunnapuu and U. Langel, *Expert Opin. Drug Delivery*, 2017, **14**, 245–255.
- 19 D. M. Copolovici, K. Langel, E. Eriste and U. Langel, *ACS Nano*, 2014, **8**, 1972–1994.
- 20 X. Y. Wang, X. H. Chen, X. C. Yang, W. Gao, B. He, W. B. Dai, H. Zhang, X. Q. Wang, J. C. Wang, X. Zhang, Z. F. Dai and Q. Zhang, *J. Nanomed. Nanotechnol.*, 2016, **12**, 387–397.
- 21 W. Gao, X. C. Yang, Z. Q. Lin, S. Y. Gao, B. He, D. Mei, D. Wang, L. Yuan, H. Zhang, W. B. Dai, X. Q. Wang, J. C. Wang, X. Zhang and Q. Zhang, *J. Biomed. Nanotechnol.*, 2016, **12**, 1183–1198.
- 22 J. R. Marks, J. Placone, K. Hristova and W. C. Wimley, *J. Am. Chem. Soc.*, 2011, **133**, 8995–9004.
- 23 X. Y. Liu, S. Timmons, Y. Z. Lin and J. Hawiger, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 11819–11824.
- 24 F. Nakayama, T. Yasuda, S. Umeda, M. Asada, T. Imamura, V. Meineke and M. Akashi, *J. Biol. Chem.*, 2011, **286**, 25823–25834.
- 25 D. F. Cai, W. Gao, B. He, W. B. Dai, H. Zhang, X. Q. Wang, J. C. Wang, X. Zhang and Q. Zhang, *Biomaterials*, 2014, **35**, 2283–2294.
- 26 C. L. Watkins, P. Brennan, C. Fegan, K. Takayama, I. Nakase, S. Futaki and A. T. Jones, *J. Controlled Release*, 2009, **140**, 237–244.
- 27 J. W. Park, E. K. Bang, E. M. Jeon and B. H. Kim, *Org. Biomol. Chem.*, 2012, **10**, 96–102.
- 28 M. Rhee and P. Davis, *J. Biol. Chem.*, 2006, **281**, 1233–1240.
- 29 B. Du, S. P. Han, H. Y. Li, F. F. Zhao, X. J. Su, X. H. Cao and Z. Z. Zhang, *Nanoscale*, 2015, **7**, 5411–5426.
- 30 N. Maeda, Y. Takeuchi, M. Takada, Y. Sadzuka, Y. Namba and N. Oku, *J. Controlled Release*, 2004, **100**, 41–52.
- 31 C. B. He, Y. P. Hu, L. C. Yin, C. Tang and C. H. Yin, *Biomaterials*, 2010, **31**, 3657–3666.
- 32 M. A. Theresa, W. K. C. Wilson, I. H. Jennifer and M. L. Kimberley, *Anti-Cancer Agents Med. Chem.*, 2006, **6**, 513–523.
- 33 M. L. Van Slooten, O. Boerman, K. Romoren, E. Kedar, D. J. Crommelin and G. Storm, *Biochim. Biophys. Acta*, 2001, **1530**, 134–145.
- 34 N. Düzgüneş and S. Nir, *Adv. Drug Delivery Rev.*, 1999, **40**, 3–18.
- 35 M. Li, H. Deng, H. Peng and Q. Wang, *J. Nanosci. Nanotechnol.*, 2014, **14**, 415–432.
- 36 R. K. Thapa, H. T. Nguyen, M. Gautam, A. Shrestha, E. S. Lee, S. K. Ku, H. G. Choi, C. S. Yong and J. O. Kim, *Drug Delivery*, 2017, **24**, 1690–1702.
- 37 S. Kolusheva, T. Shahal and R. Jelinek, *Biochemistry*, 2000, **39**, 15851–15859.
- 38 Y. Wang, S. Ma, Z. Xie and H. Zhang, *Colloids Surf., B*, 2014, **116**, 41–48.
- 39 D. Zhu, S. Wu, C. Hu, Z. Chen, H. Wang, F. Fan, Y. Qin, C. Wang, H. Sun, X. Leng, D. Kong and L. Zhang, *Acta Biomater.*, 2017, **58**, 399–412.
- 40 P. Sharma, S. Brown, G. Walter, S. Santra and B. Moudgil, *Adv. Colloid Interface Sci.*, 2006, **123**, 471–485.
- 41 T. Lammers, F. Kiessling, W. E. Hennink and G. Storm, *J. Controlled Release*, 2012, **161**, 175–187.
- 42 L. Jiang, L. Li, X. D. He, Q. Y. Yi, B. He, J. Cao, W. S. Pan and Z. W. Gu, *Biomaterials*, 2015, **52**, 126–139.
- 43 E. Gullotti and Y. Yeo, *Mol. Pharm.*, 2009, **6**, 1041–1051.
- 44 K. Saar, M. Lindgren, M. Hansen, E. Eiríksdóttir, Y. Jiang, K. Rosenthal-Aizman, M. Sassian and Ü. Langel, *Anal. Biochem.*, 2005, **345**, 55–65.

